{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:33:16Z","timestamp":1791343996597,"version":"4.3.1"},"reference-count":60,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:p>\n                    Systemic mastocytosis (SM) is a heterogeneous disease with 6 subtypes, including systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease (SM-AHNMD). Bone marrow biopsy specimens show multifocal aggregates of mast cells with predominantly spindle-shaped morphology associated with a myeloid or, less frequently, a lymphoproliferative neoplasm defined by World Health Organization criteria. Neoplastic mast cells abnormally express CD2 and\/or CD25, which may be detected by flow cytometry or immunohistochemistry. The pathogenesis of SM-AHNMD is not well understood; however, combined\n                    <jats:italic>KIT<\/jats:italic>\n                    tyrosine kinase receptor mutations and additional genetic events in myeloid stem cells may have a pathogenic role. Reactive mast cell hyperplasia, monocytic\/histiocytic proliferations, SM without sufficient criteria for a diagnosis of AHNMD, atypical mast cells associated with\n                    <jats:italic>PDGFRA<\/jats:italic>\n                    rearrangements, and other tryptase-positive myeloid proliferations should be excluded. Overall, the prognosis is poor and largely related to the AHNMD. Cytoreductive therapies, splenectomy, allogeneic bone marrow transplant, and tyrosine kinase inhibitors, excluding imatinib, may have potential efficacy in the treatment of these diseases.\n                  <\/jats:p>","DOI":"10.5858\/arpa.2011-0325-rs","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T15:53:59Z","timestamp":1340898839000},"page":"832-838","source":"Crossref","is-referenced-by-count":32,"title":["Systemic Mastocytosis With Associated Clonal Hematologic Nonmast Cell Lineage Disease: A Clinicopathologic Review"],"prefix":"10.5858","volume":"136","author":[{"given":"Maggie M.","family":"Stoecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"key":"arpa-136-07-832-838-b01","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed","first-page":"54","article-title":"Mastocytosis","author":"Horny\n              HP,","year":"2008","unstructured":"Horny\n              HP, \n            \n              Metcalfe\n              DD, \n            \n              Bennett\n              JM\n            , et al. \n          Mastocytosis. In: SwerdlowSH, Campo, E, HarrisNL, et al., eds. . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edGeneva, Switzerland: IARC Press; 2008:54\u201363. World Health Organization Classification of Tumours; vol\u00a02."},{"issue":"7","key":"arpa-136-07-832-838-b02","series-title":"Leuk Res","first-page":"603","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent\n              P,","year":"2001","unstructured":"Valent\n              P, \n            \n              Horny\n              HP, \n            \n              Escribano\n              L\n            , et al. \n          Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603\u2013625."},{"issue":"23","key":"arpa-136-07-832-838-b03","series-title":"Blood","first-page":"5727","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim\n              KH,","year":"2009","unstructured":"Lim\n              KH, \n            \n              Tefferi\n              A, \n            \n              Lasho\n              TL\n            , et al. \n          Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727\u20135736."},{"issue":"1","key":"arpa-136-07-832-838-b04","series-title":"Am J Hematol","first-page":"12","article-title":"Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-KIT mutations","volume":"73","author":"Pullarkat\n              VA,","year":"2003","unstructured":"Pullarkat\n              VA, \n            \n              Bueso-Ramos\n              C, \n            \n              Lai\n              R\n            , et al. \n          Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-KIT mutations. Am J Hematol. 2003;73(1):12\u201317."},{"issue":"4","key":"arpa-136-07-832-838-b05","series-title":"Blood","first-page":"946","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe\n              DD","year":"2008","unstructured":"Metcalfe\n              DD\n            \n          . Mast cells and mastocytosis. Blood. 2008;112(4):946\u2013956."},{"issue":"18","key":"arpa-136-07-832-838-b06","series-title":"Blood","first-page":"3769","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani\n              A,","year":"2009","unstructured":"Pardanani\n              A, \n            \n              Lim\n              KH, \n            \n              Lasho\n              TL\n            \n          . Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769\u20133772."},{"issue":"17","key":"arpa-136-07-832-838-b07","series-title":"J Clin Oncol","first-page":"514","article-title":"Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase","volume":"29","author":"Vigil\n              CE,","year":"2011","unstructured":"Vigil\n              CE, \n            \n              Wang\n              SA, \n            \n              Cortes\n              JE\n            , et al. \n          Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011;29(17):514\u2013516."},{"issue":"7","key":"arpa-136-07-832-838-b08","series-title":"Leuk Res","first-page":"563","article-title":"Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis","volume":"25","author":"Escribano\n              L,","year":"2001","unstructured":"Escribano\n              L, \n            \n              Diaz-Agustin\n              B, \n            \n              Bellas\n              C\n            , et al. \n          Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001;25(7):563\u2013570."},{"issue":"1","key":"arpa-136-07-832-838-b09","series-title":"Mod Pathol","first-page":"50","article-title":"Utility of the World Health Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow","volume":"22","author":"Johnson\n              MR,","year":"2009","unstructured":"Johnson\n              MR, \n            \n              Verstovsek\n              S, \n            \n              Jorgensen\n              JL\n            \n          . Utility of the World Health Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009;22(1):50\u201357."},{"issue":"23","key":"arpa-136-07-832-838-b10","series-title":"Proc Natl Acad Sci U S A","first-page":"10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in the peripheral blood mononuclear cells in patients who have mastocytosis with an associated hematological disorder","volume":"92","author":"Nagata\n              H,","year":"1995","unstructured":"Nagata\n              H, \n            \n              Worobec\n              AS, \n            \n              Oh\n              CK\n            , et al. \n          Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in the peripheral blood mononuclear cells in patients who have mastocytosis with an associated hematological disorder. Proc Natl Acad Sci U S A. 1995;92(23):10560\u201310564."},{"issue":"1","key":"arpa-136-07-832-838-b11","series-title":"J Clin Pathol","first-page":"109","article-title":"Detection of the c-KIT D816V mutation in systemic mastocytosis by allele-specific PCR","volume":"61","author":"Schumacher\n              JA,","year":"2008","unstructured":"Schumacher\n              JA, \n            \n              Elenitoba\n              KSJ, \n            \n              Lim\n              MS\n            \n          . Detection of the c-KIT D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol. 2008;61(1):109\u2013114."},{"issue":"1","key":"arpa-136-07-832-838-b12","series-title":"J Hematopathol","first-page":"27","article-title":"Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia","volume":"2","author":"Pullarkat\n              ST,","year":"2009","unstructured":"Pullarkat\n              ST, \n            \n              Pullarkat\n              V, \n            \n              Kroft\n              SH\n            , et al. \n          Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. J Hematopathol. 2009;2(1):27\u201333."},{"issue":"5","key":"arpa-136-07-832-838-b13","series-title":"J Immunol","first-page":"1410","article-title":"Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells","volume":"146","author":"Kirshenbaum\n              AS,","year":"1991","unstructured":"Kirshenbaum\n              AS, \n            \n              Kessler\n              SW, \n            \n              Goff\n              JP, \n            \n              Metcalfe\n              DD\n            \n          . Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol. 1991;146(5):1410\u20131415."},{"issue":"8","key":"arpa-136-07-832-838-b14","series-title":"Br J Pharmacol","first-page":"1572","article-title":"Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders","volume":"154","author":"Jensen\n              BM,","year":"2008","unstructured":"Jensen\n              BM, \n            \n              Akin\n              C, \n            \n              Gilfillan\n              AM\n            \n          . Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol. 2008;154(8):1572\u20131582."},{"issue":"1","key":"arpa-136-07-832-838-b15","series-title":"Br J Haematol","first-page":"12","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao\n              A,","year":"2007","unstructured":"Orfao\n              A, \n            \n              Garcia-Montero\n              AC, \n            \n              Sanchez\n              L, \n            \n              Escribano\n              L\n            \n          . Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007;138(1):12\u201330."},{"issue":"6","key":"arpa-136-07-832-838-b16","series-title":"Am J Pathol","first-page":"2416","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner\n              C,","year":"2009","unstructured":"Baumgartner\n              C, \n            \n              Cerny-Reiterer\n              S, \n            \n              Sonneck\n              K\n            , et al. \n          Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009;175(6):2416\u20132429."},{"issue":"5","key":"arpa-136-07-832-838-b17","series-title":"J Pathol","first-page":"586","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar\n              K,","year":"2010","unstructured":"Sotlar\n              K, \n            \n              Colak\n              S, \n            \n              Bache\n              A\n            , et al. \n          Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220(5):586\u2013595."},{"issue":"2","key":"arpa-136-07-832-838-b18","series-title":"Leuk Res","first-page":"261","article-title":"Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone","volume":"31","author":"Pullarkat\n              V,","year":"2007","unstructured":"Pullarkat\n              V, \n            \n              Bedell\n              V, \n            \n              Kim\n              Y\n            , et al. \n          Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res. 2007;31(2):261\u2013265."},{"issue":"2","key":"arpa-136-07-832-838-b19","series-title":"Eur J Clin Invest","first-page":"153","article-title":"FIP1L1\/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis","volume":"37","author":"Valent\n              P,","year":"2007","unstructured":"Valent\n              P, \n            \n              Akin\n              C, \n            \n              Metcalfe\n              DD\n            \n          . FIP1L1\/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007;37(2):153\u2013154."},{"issue":"3","key":"arpa-136-07-832-838-b20","series-title":"J Clin Pathol","first-page":"298","article-title":"The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers","volume":"59","author":"Horny\n              HP,","year":"2006","unstructured":"Horny\n              HP, \n            \n              Sotlar\n              K, \n            \n              Stellmacher\n              F\n            , et al. \n          The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol. 2006;59(3):298\u2013302."},{"issue":"1","key":"arpa-136-07-832-838-b21","series-title":"Surgery","first-page":"94","article-title":"Splenectomy in the management of systemic mast cell disease","volume":"107","author":"Friedman\n              B,","year":"1990","unstructured":"Friedman\n              B, \n            \n              Darling\n              G, \n            \n              Norton\n              J, \n            \n              Hamby\n              L, \n            \n              Metcalfe\n              D\n            \n          . Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107(1):94\u2013100."},{"issue":"1","key":"arpa-136-07-832-838-b22","series-title":"Am J Hematol","first-page":"24","article-title":"Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: a review of forty cases","volume":"57","author":"Przepiorka\n              D,","year":"1998","unstructured":"Przepiorka\n              D, \n            \n              Giralt\n              S, \n            \n              Khouri\n              I, \n            \n              Champlin\n              R, \n            \n              Bueso-Ramos\n              C\n            \n          . Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: a review of forty cases. Am J Hematol. 1998;57(1):24\u201328."},{"issue":"12","key":"arpa-136-07-832-838-b23","series-title":"J Clin Oncol","first-page":"3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd\n              JC,","year":"1999","unstructured":"Byrd\n              JC, \n            \n              Dodge\n              RK, \n            \n              Carroll\n              A\n            , et al. \n          Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767\u20133775."},{"issue":"24","key":"arpa-136-07-832-838-b24","series-title":"J Clin Oncol","first-page":"3904","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study","volume":"24","author":"Paschka\n              P,","year":"2006","unstructured":"Paschka\n              P, \n            \n              Marcucci\n              G, \n            \n              Ruppert\n              AS\n            , et al. \n          Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006;24(24):3904\u20133911."},{"issue":"12","key":"arpa-136-07-832-838-b25","series-title":"Mol Cancer Ther","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI 571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost\n              MJ,","year":"2002","unstructured":"Frost\n              MJ, \n            \n              Ferrao\n              PT, \n            \n              Hughes\n              TP, \n            \n              Ashman, LK\n          . Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI 571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1(12):1115\u20131124."},{"issue":"1","key":"arpa-136-07-832-838-b26","series-title":"Blood","first-page":"286","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah\n              NP,","year":"2006","unstructured":"Shah\n              NP, \n            \n              Lee\n              FY, \n            \n              Luo\n              R, \n            \n              Jiang\n              Y, \n            \n              Donker\n              M, \n            \n              Akin\n              C\n            \n          . Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286\u2013291."},{"issue":"5","key":"arpa-136-07-832-838-b27","series-title":"Leuk Res","first-page":"735","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V","volume":"33","author":"Ustun\n              C,","year":"2009","unstructured":"Ustun\n              C, \n            \n              Corless\n              CL, \n            \n              Savage\n              N\n            , et al. \n          Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V. Leuk Res. 2009;33(5):735\u2013741."},{"issue":"8","key":"arpa-136-07-832-838-b28","series-title":"Blood","first-page":"2865","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib\n              J,","year":"2005","unstructured":"Gotlib\n              J, \n            \n              Berube\n              C, \n            \n              Growney\n              JD\n            , et al. \n          Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865\u20132870."},{"issue":"11","key":"arpa-136-07-832-838-b29","series-title":"Haematologica","first-page":"1451","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner\n              KV,","year":"2007","unstructured":"Gleixner\n              KV, \n            \n              Mayerhofer\n              M, \n            \n              Sonneck\n              K\n            , et al. \n          Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007;92(11):1451\u20131459."},{"issue":"9","key":"arpa-136-07-832-838-b30","series-title":"Leukemia","first-page":"1670","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"Von Bubnoff\n              N,","year":"2005","unstructured":"Von Bubnoff\n              N, \n            \n              Gorantla\n              SHP, \n            \n              Kancha\n              RK, \n            \n              Lordick\n              F, \n            \n              Peschel\n              C, \n            \n              Duyster\n              J\n            \n          . The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia. 2005;19(9):1670\u20131671."},{"key":"arpa-136-07-832-838-b01","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed","first-page":"54","article-title":"Mastocytosis","author":"Horny\n              HP,","year":"2008","unstructured":"Horny\n              HP, \n            \n              Metcalfe\n              DD, \n            \n              Bennett\n              JM\n            , et al. \n          Mastocytosis. In: SwerdlowSH, Campo, E, HarrisNL, et al., eds. . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edGeneva, Switzerland: IARC Press; 2008:54\u201363. World Health Organization Classification of Tumours; vol\u00a02."},{"issue":"7","key":"arpa-136-07-832-838-b02","series-title":"Leuk Res","first-page":"603","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent\n              P,","year":"2001","unstructured":"Valent\n              P, \n            \n              Horny\n              HP, \n            \n              Escribano\n              L\n            , et al. \n          Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603\u2013625."},{"issue":"23","key":"arpa-136-07-832-838-b03","series-title":"Blood","first-page":"5727","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim\n              KH,","year":"2009","unstructured":"Lim\n              KH, \n            \n              Tefferi\n              A, \n            \n              Lasho\n              TL\n            , et al. \n          Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727\u20135736."},{"issue":"1","key":"arpa-136-07-832-838-b04","series-title":"Am J Hematol","first-page":"12","article-title":"Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-KIT mutations","volume":"73","author":"Pullarkat\n              VA,","year":"2003","unstructured":"Pullarkat\n              VA, \n            \n              Bueso-Ramos\n              C, \n            \n              Lai\n              R\n            , et al. \n          Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-KIT mutations. Am J Hematol. 2003;73(1):12\u201317."},{"issue":"4","key":"arpa-136-07-832-838-b05","series-title":"Blood","first-page":"946","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe\n              DD","year":"2008","unstructured":"Metcalfe\n              DD\n            \n          . Mast cells and mastocytosis. Blood. 2008;112(4):946\u2013956."},{"issue":"18","key":"arpa-136-07-832-838-b06","series-title":"Blood","first-page":"3769","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani\n              A,","year":"2009","unstructured":"Pardanani\n              A, \n            \n              Lim\n              KH, \n            \n              Lasho\n              TL\n            \n          . Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769\u20133772."},{"issue":"17","key":"arpa-136-07-832-838-b07","series-title":"J Clin Oncol","first-page":"514","article-title":"Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase","volume":"29","author":"Vigil\n              CE,","year":"2011","unstructured":"Vigil\n              CE, \n            \n              Wang\n              SA, \n            \n              Cortes\n              JE\n            , et al. \n          Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol. 2011;29(17):514\u2013516."},{"issue":"7","key":"arpa-136-07-832-838-b08","series-title":"Leuk Res","first-page":"563","article-title":"Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis","volume":"25","author":"Escribano\n              L,","year":"2001","unstructured":"Escribano\n              L, \n            \n              Diaz-Agustin\n              B, \n            \n              Bellas\n              C\n            , et al. \n          Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001;25(7):563\u2013570."},{"issue":"1","key":"arpa-136-07-832-838-b09","series-title":"Mod Pathol","first-page":"50","article-title":"Utility of the World Health Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow","volume":"22","author":"Johnson\n              MR,","year":"2009","unstructured":"Johnson\n              MR, \n            \n              Verstovsek\n              S, \n            \n              Jorgensen\n              JL\n            \n          . Utility of the World Health Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol. 2009;22(1):50\u201357."},{"issue":"23","key":"arpa-136-07-832-838-b10","series-title":"Proc Natl Acad Sci U S A","first-page":"10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in the peripheral blood mononuclear cells in patients who have mastocytosis with an associated hematological disorder","volume":"92","author":"Nagata\n              H,","year":"1995","unstructured":"Nagata\n              H, \n            \n              Worobec\n              AS, \n            \n              Oh\n              CK\n            , et al. \n          Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in the peripheral blood mononuclear cells in patients who have mastocytosis with an associated hematological disorder. Proc Natl Acad Sci U S A. 1995;92(23):10560\u201310564."},{"issue":"1","key":"arpa-136-07-832-838-b11","series-title":"J Clin Pathol","first-page":"109","article-title":"Detection of the c-KIT D816V mutation in systemic mastocytosis by allele-specific PCR","volume":"61","author":"Schumacher\n              JA,","year":"2008","unstructured":"Schumacher\n              JA, \n            \n              Elenitoba\n              KSJ, \n            \n              Lim\n              MS\n            \n          . Detection of the c-KIT D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol. 2008;61(1):109\u2013114."},{"issue":"1","key":"arpa-136-07-832-838-b12","series-title":"J Hematopathol","first-page":"27","article-title":"Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia","volume":"2","author":"Pullarkat\n              ST,","year":"2009","unstructured":"Pullarkat\n              ST, \n            \n              Pullarkat\n              V, \n            \n              Kroft\n              SH\n            , et al. \n          Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. J Hematopathol. 2009;2(1):27\u201333."},{"issue":"5","key":"arpa-136-07-832-838-b13","series-title":"J Immunol","first-page":"1410","article-title":"Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells","volume":"146","author":"Kirshenbaum\n              AS,","year":"1991","unstructured":"Kirshenbaum\n              AS, \n            \n              Kessler\n              SW, \n            \n              Goff\n              JP, \n            \n              Metcalfe\n              DD\n            \n          . Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol. 1991;146(5):1410\u20131415."},{"issue":"8","key":"arpa-136-07-832-838-b14","series-title":"Br J Pharmacol","first-page":"1572","article-title":"Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders","volume":"154","author":"Jensen\n              BM,","year":"2008","unstructured":"Jensen\n              BM, \n            \n              Akin\n              C, \n            \n              Gilfillan\n              AM\n            \n          . Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol. 2008;154(8):1572\u20131582."},{"issue":"1","key":"arpa-136-07-832-838-b15","series-title":"Br J Haematol","first-page":"12","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao\n              A,","year":"2007","unstructured":"Orfao\n              A, \n            \n              Garcia-Montero\n              AC, \n            \n              Sanchez\n              L, \n            \n              Escribano\n              L\n            \n          . Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007;138(1):12\u201330."},{"issue":"6","key":"arpa-136-07-832-838-b16","series-title":"Am J Pathol","first-page":"2416","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner\n              C,","year":"2009","unstructured":"Baumgartner\n              C, \n            \n              Cerny-Reiterer\n              S, \n            \n              Sonneck\n              K\n            , et al. \n          Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009;175(6):2416\u20132429."},{"issue":"5","key":"arpa-136-07-832-838-b17","series-title":"J Pathol","first-page":"586","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar\n              K,","year":"2010","unstructured":"Sotlar\n              K, \n            \n              Colak\n              S, \n            \n              Bache\n              A\n            , et al. \n          Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220(5):586\u2013595."},{"issue":"2","key":"arpa-136-07-832-838-b18","series-title":"Leuk Res","first-page":"261","article-title":"Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone","volume":"31","author":"Pullarkat\n              V,","year":"2007","unstructured":"Pullarkat\n              V, \n            \n              Bedell\n              V, \n            \n              Kim\n              Y\n            , et al. \n          Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res. 2007;31(2):261\u2013265."},{"issue":"2","key":"arpa-136-07-832-838-b19","series-title":"Eur J Clin Invest","first-page":"153","article-title":"FIP1L1\/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis","volume":"37","author":"Valent\n              P,","year":"2007","unstructured":"Valent\n              P, \n            \n              Akin\n              C, \n            \n              Metcalfe\n              DD\n            \n          . FIP1L1\/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007;37(2):153\u2013154."},{"issue":"3","key":"arpa-136-07-832-838-b20","series-title":"J Clin Pathol","first-page":"298","article-title":"The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers","volume":"59","author":"Horny\n              HP,","year":"2006","unstructured":"Horny\n              HP, \n            \n              Sotlar\n              K, \n            \n              Stellmacher\n              F\n            , et al. \n          The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol. 2006;59(3):298\u2013302."},{"issue":"1","key":"arpa-136-07-832-838-b21","series-title":"Surgery","first-page":"94","article-title":"Splenectomy in the management of systemic mast cell disease","volume":"107","author":"Friedman\n              B,","year":"1990","unstructured":"Friedman\n              B, \n            \n              Darling\n              G, \n            \n              Norton\n              J, \n            \n              Hamby\n              L, \n            \n              Metcalfe\n              D\n            \n          . Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107(1):94\u2013100."},{"issue":"1","key":"arpa-136-07-832-838-b22","series-title":"Am J Hematol","first-page":"24","article-title":"Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: a review of forty cases","volume":"57","author":"Przepiorka\n              D,","year":"1998","unstructured":"Przepiorka\n              D, \n            \n              Giralt\n              S, \n            \n              Khouri\n              I, \n            \n              Champlin\n              R, \n            \n              Bueso-Ramos\n              C\n            \n          . Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: a review of forty cases. Am J Hematol. 1998;57(1):24\u201328."},{"issue":"12","key":"arpa-136-07-832-838-b23","series-title":"J Clin Oncol","first-page":"3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd\n              JC,","year":"1999","unstructured":"Byrd\n              JC, \n            \n              Dodge\n              RK, \n            \n              Carroll\n              A\n            , et al. \n          Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767\u20133775."},{"issue":"24","key":"arpa-136-07-832-838-b24","series-title":"J Clin Oncol","first-page":"3904","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study","volume":"24","author":"Paschka\n              P,","year":"2006","unstructured":"Paschka\n              P, \n            \n              Marcucci\n              G, \n            \n              Ruppert\n              AS\n            , et al. \n          Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006;24(24):3904\u20133911."},{"issue":"12","key":"arpa-136-07-832-838-b25","series-title":"Mol Cancer Ther","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI 571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost\n              MJ,","year":"2002","unstructured":"Frost\n              MJ, \n            \n              Ferrao\n              PT, \n            \n              Hughes\n              TP, \n            \n              Ashman, LK\n          . Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI 571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1(12):1115\u20131124."},{"issue":"1","key":"arpa-136-07-832-838-b26","series-title":"Blood","first-page":"286","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah\n              NP,","year":"2006","unstructured":"Shah\n              NP, \n            \n              Lee\n              FY, \n            \n              Luo\n              R, \n            \n              Jiang\n              Y, \n            \n              Donker\n              M, \n            \n              Akin\n              C\n            \n          . Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286\u2013291."},{"issue":"5","key":"arpa-136-07-832-838-b27","series-title":"Leuk Res","first-page":"735","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V","volume":"33","author":"Ustun\n              C,","year":"2009","unstructured":"Ustun\n              C, \n            \n              Corless\n              CL, \n            \n              Savage\n              N\n            , et al. \n          Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V. Leuk Res. 2009;33(5):735\u2013741."},{"issue":"8","key":"arpa-136-07-832-838-b28","series-title":"Blood","first-page":"2865","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib\n              J,","year":"2005","unstructured":"Gotlib\n              J, \n            \n              Berube\n              C, \n            \n              Growney\n              JD\n            , et al. \n          Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865\u20132870."},{"issue":"11","key":"arpa-136-07-832-838-b29","series-title":"Haematologica","first-page":"1451","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner\n              KV,","year":"2007","unstructured":"Gleixner\n              KV, \n            \n              Mayerhofer\n              M, \n            \n              Sonneck\n              K\n            , et al. \n          Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007;92(11):1451\u20131459."},{"issue":"9","key":"arpa-136-07-832-838-b30","series-title":"Leukemia","first-page":"1670","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"Von Bubnoff\n              N,","year":"2005","unstructured":"Von Bubnoff\n              N, \n            \n              Gorantla\n              SHP, \n            \n              Kancha\n              RK, \n            \n              Lordick\n              F, \n            \n              Peschel\n              C, \n            \n              Duyster\n              J\n            \n          . The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia. 2005;19(9):1670\u20131671."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/136\/7\/article-p832.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/136\/7\/832\/1440358\/arpa_2011-0325-rs.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/136\/7\/article-p832.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/136\/7\/article-p832.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:13:20Z","timestamp":1770772400000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/136\/7\/article-p832.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":60,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2011-0325-rs","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}